Press Room

Filter by year:
July 1, 2020

ProterixBio licenses COVID-19 serology test from Massachusetts General Hospital

Billerica, MA, July 1, 2020: ProterixBio, Inc. today announced completing a licensing agreement with the Massachusetts General Hospital for a COVID-19 serology assay. The assay was developed and validated by researchers at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University which is a joint venture of Harvard University, Massachusetts…

Read more
June 25, 2020

Oppilan Pharma Announces Positive Phase 1 Data for its Ulcerative Colitis Drug OPL-002 at Digestive Disease Week 2020 Virtual Scientific Program

Potential best-in-class profile for an oral sphingosine-1-phosphate receptor modulator – Dose-dependent reduction in circulating lymphocytes –– Rapid lymphocyte recovery after cessation of dosing –– Phase 2 study in ulcerative colitis patients in 4Q 2020 – ENCINITAS, California and Cambridge, United Kingdom, June 23, 2020 – Oppilan Pharma, Ltd., a clinical-stage biopharmaceutical company focused on developing…

Read more
April 16, 2020

As the Global Crisis Evolves, Publishers are Focusing on Digital with a Renewed Sense of Urgency

By understanding their platform’s capabilities and following best practices, publishers can be confident in their digital strategy during these uncertain times. There’s little doubt that the COVID-19 pandemic has changed the digital publishing landscape. Supply chain disruptions and reduced ad spending are forcing publishers to take a hard look at their short and long-term digital…

Read more
March 5, 2020

Perceptimed Awarded NIH Development Grant

PERCEPTIMED AWARDED $1.5M NIH DEVELOPMENT GRANT   MOUNTAIN VIEW, CA – PerceptiMed, Inc., was awarded a $1.5 million grant from the National Institutes of Health (NIH) to develop and test a secure, individual medication system for long-term care facilities.  Dr. Alan Jacobs, CEO and founder of PerceptiMed will serve as the principal investor and scientific…

Read more
March 5, 2020

Perceptimed Founder Jacobs To Speak At Bio2device Group Event

PERCEPTIMED FOUNDER JACOBS TO SPEAK AT BIO2DEVICE GROUP EVENT MOUNTAIN VIEW, CA – April 25, 2014 – “Preventing Drug-Related Patient Injury and Death with Advanced, Cost-Effective Technology” is the topic Alan Jacobs, M.D., Ph.D., CEO and founder of PerceptiMed, will address at the Bio2Device lecture.  The lecture will take place May 6th at the Sunnyvale…

Read more
January 8, 2020

NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic

Two new US investors; lead investor, venBio Partners and Sofinnova Investments, join syndicate of existing investors Richard Gaster, M.D., Ph.D., Principal at venBio Partners, and Maha Katabi, Ph.D., CFA, Partner at Sofinnova Investments join the Board Proceeds will be used to progress the SEFA development pipeline: Completion of Phase 2b study of lead programme Icosabutate…

Read more
December 21, 2019

2019: A Look Back

2019 was an exciting and busy year for us! As we take a look back at some of our milestones, we’d like to give a big thank you to all of our publishers. We’re looking forward to what’s in store in the coming year! We’re happy to report that 2019 was one of our most…

Read more